All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Not Used | NCIT_C69062 | [Not employed or utilized.] |
| Missing Value Reason | NCIT_C48655 | [A specific reason explaining why a meaningful value is not available. A meaningful value answers the question posed by a Data Element Concept. In contrast, a Missing Value Reason answers the implicit question "Why is there no 'meaningful' value?", when there is none.] |
| Throat Spray Dosage Form | NCIT_C69063 | [A spray intended for administration to the mucosa of the throat.] |
| Spray Dosage Form | NCIT_C42989 | [A solution or suspension composed of active and/or inert ingredient(s) in oil or water, typically dispensed from an atomizer or nebulizer.] |
| Nasal Dosage Form | NCIT_C69064 | [A substance intended for administration in the nares.] |
| Rindopepimut | NCIT_C69076 | [A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.] |
| Antineoplastic Vaccine | NCIT_C1663 | [A type of vaccine that prevents or treats cancer.] |
| Planned Activity Repeat Duration | NCIT_C94000 | [The period of time over which the planned activity is repeated.] |
| Repeat Duration | NCIT_C93647 | [The period of time over which the event or activity is repeated.] |
| Anti-Hemophilia Factor Unit | NCIT_C69077 | [One international unit of antihemophilic activity is equivalent to the quantity of antihemophilic factor (Factor VIII) present in 1 mL of normal human plasma.] |
| Unit of Biological and Biochemical Measurement | NCIT_C48463 | |
| Planned Activity Repeat Frequency Code | NCIT_C94001 | [A coded value specifying the number of occurrences of a planned activity within a given time period.] |
| Repeat Frequency Code | NCIT_C93648 | [A coded value specifying the number of occurrences of an event within a given time period.] |
| Net Weight | NCIT_C69078 | [The weight of the content in a container without the weight of the container or any other packaging material.] |
| Weight | NCIT_C25208 | [The vertical force exerted by a mass as a result of gravity.] |
| Planned Activity Repeat Frequency Ratio | NCIT_C94002 | [A ratio representing the number of occurrences of a planned activity within a given time period.] |
| Repeat Frequency Ratio | NCIT_C93649 | [A ratio representing the number of occurrences of an event within a given time period.] |
| Polymeric Camptothecin Prodrug XMT-1001 | NCIT_C69079 | [A polymeric prodrug of camptothecin (CPT) with potential antineoplastic activity. Polymeric camptothecin prodrug XMT-1001 consists of CPT conjugated to the 60-70 kDa, inert, bio-degradable, hydrophilic copolymer poly[1-hydroxymethylene hydroxymethyl formal] (PHF). Through a dual-phase, non-enzymatic release mechanism, CPT is first released in plasma from XMT-1001 as the lipophilic prodrugs CPT-SI (a succinimidoglycinate derivative) and CPT-SA (a succinamidoyl glycinate derivative), which are then hydrolyzed within tissues to release the lactone form of CPT. CPT inhibits the catalytic activity of DNA topoisomerase I, thereby inhibiting DNA replication and inducing apoptosis. This agent may exhibit a more favorable pharmacokinetic profile than other agents in the same class.] |
| Topoisomerase-I Inhibitor | NCIT_C1904 | [Any substance that inhibits topoisomerase-I, a topoisomerase that relieves torsional stress in a DNA molecule by cutting only one strand of the DNA double helix. Inhibition of topoisomerase-I causes DNA damage, inhibition of DNA replication, and apoptosis.] |
| Planned Activity Repeat Quantity | NCIT_C94003 | [The number of times the planned activity occurs.] |